初诊卵巢癌腹腔化疗联合PARP抑制剂与贝伐珠单抗的1期剂量递增研究
OBJECTIVE: We assessed the safety and maximum tolerated dose (MTD) of the poly ADP-ribose polymerase (PARP) inhibitor olaparib with intravenous (IV)/intraperitoneal (IP) cisplatin/paclitaxel and IV bevacizumab, followed by olaparib and bevacizumab maintenance, in patients with ne…
要点
- 奥拉帕利联合IV/IP顺铂紫杉醇及贝伐珠单抗的MTD为100 mg每日两次
- 3/4级毒性以中性粒细胞减少(56%)最常见
- 奥拉帕利维持治疗中36%患者需减量
核心结论
- 奥拉帕利间歇给药联合同期IV/IP顺铂/紫杉醇及贝伐珠单抗的MTD为100 mg每日两次。
- 非血液学毒性以低级别为主。
- 奥拉帕利维持治疗中约三分之一患者需减量。
研究设计与样本
- 队列1(奥拉帕利50 mg)8例,队列2(100 mg)3例,队列3(200 mg)6例。
- 主要终点为奥拉帕利、化疗与贝伐珠单抗联合的最大耐受剂量。
主要发现
- 中位年龄57岁(47-73),94%为III期疾病,29%有胚系BRCA突变。
- 队列3的6例患者中2例出现剂量限制性毒性。
- 3/4级毒性包括中性粒细胞减少(56%)、淋巴细胞减少(31%)、贫血(25%)和乏力(19%)。
- 88%与81%的患者分别开始奥拉帕利和贝伐珠单抗维持治疗,75%与50%分别完成。
- 中位无进展生存期为33个月(26.2-NA)。
关键数值与推荐
- 治疗方案:第1-6周期第1天静脉紫杉醇135 mg/m2/3小时,自第2周期起加贝伐珠单抗15 mg/kg。
- 第2天腹腔顺铂75 mg/m2,第2-8天奥拉帕利(50/100/200 mg每日两次),第8天腹腔紫杉醇60 mg/m2,21天为一周期。
- 维持治疗(第7-22周期):奥拉帕利300 mg每日两次,第1天贝伐珠单抗15 mg/kg。
- 奥拉帕利维持治疗中36%患者需减量。
临床怎么用
- 对于初诊接受初次减瘤术的卵巢癌患者,可考虑奥拉帕利100 mg每日两次间歇给药联合IV/IP铂类紫杉醇化疗及贝伐珠单抗。
- 联合方案血液学毒性常见,需监测中性粒细胞减少等不良反应。
- 奥拉帕利维持阶段需关注减量需求。
局限性
- 未设对照组,疗效数据需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the safety and maximum tolerated dose (MTD) of the poly ADP-ribose polymerase (PARP) inhibitor olaparib with intravenous (IV)/intraperitoneal (IP) cisplatin/paclitaxel and IV bevacizumab, followed by olaparib and bevacizumab maintenance, in patients with newly diagnosed ovarian cancer who had undergone primary debulking surgery. METHODS: Treatment included: (Cycles 1-6) Day 1, IV paclitaxel 135 mg/m2/3 h + (from Cycle 2 onward) bevacizumab 15 mg/kg; Day 2, IP cisplatin 75 mg/m2; Days 2-8, olaparib (50/100/200 mg BID); Day 8, IP paclitaxel 60 mg/m2 of a 21-day cycle. Maintenance (Cycles 7-22) included: olaparib 300 mg BID and bevacizumab 15 mg/kg Day 1. The primary endpoint was MTD of olaparib, chemotherapy, and bevacizumab. RESULTS: Seventeen women were treated (Cohort 1 [50 mg olaparib], 8 patients; Cohort 2 [100 mg], 3 patients; and Cohort 3 [200 mg], 6 patients). Median age was 57 years (47-73); 94% had stage III disease; 29% had a germline BRCA mutation. Two of 6 patients in Cohort 3 experienced a dose-limiting toxicity (DLT). Grade 3/4 toxicities included: neutropenia (56%), lymphopenia (31%), anemia (25%), and fatigue (19%). Most patients started (88%, 81%) and completed (75%, 50%) maintenance olaparib and bevacizumab, respectively; 36% of patients on olaparib maintenance required a dose reduction. Median PFS was 33 months (26.2-NA). CONCLUSIONS: The MTD of intermittently dosed olaparib with concurrent IV/IP cisplatin/paclitaxel and bevacizumab is 100 mg BID. Non-hematologic toxicities were predominantly low grade. One-third of patients on olaparib maintenance required dose reduction.
引用
- Cadoo KA, Grisham RN, O'Cearbhaill RE, et al. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecol Oncol. 2020. PMID: 31959492. doi:10.1016/j.ygyno.2020.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。